Showing results (251-260 of 286) with videos related to
Sort By:
Pageof 29
Translational Lung Cancer Research|February 11, 2021
Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET)Shinji Takeuchi, Noriko Yanagitani, Takashi Seto, et al.Clinical Genitourinary Cancer|October 11, 2025
Comprehensive Evaluation of Androgen Receptor Pathway Inhibitors in Metastatic Castration-Sensitive Prostate Cancer: A Multicenter Inverse Probability of Treatment Weighting-Based StudyKeita Kobayashi, Takanori Tokunaga, Kazuhiro Nagao, et al.Hepatology (Baltimore, Md.)|May 1, 2021
Treatment of Retinoblastoma 1-Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination TherapyJindan Sheng, Susumu Kohno, Nobuhiro Okada, et al.International Journal of Clinical Oncology|June 17, 2015
Use of preoperative performance status and hemoglobin concentration to predict overall survival for patients aged ≥ 75 years after radical cystectomy for treatment of bladder cancerTakahiko Hara, Hideyasu Matsuyama, Yoriaki Kamiryo, et al.Scientific Reports|August 14, 2015
Elevated β-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugsAsuka Nakata, Ryo Yoshida, Rui Yamaguchi, et al.Japanese Journal of Clinical Oncology|June 27, 2019
Phase I/II study of intermitted erlotinib in combination with docetaxel in patients with recurrent non-small cell lung cancer (WJOG4708L)Tatsuo Kimura, Tomoya Kawaguchi, Yasutaka Chiba, et al.Frontiers in Oncology|April 16, 2025
Case Report: Medullary carcinoma of the pancreas with MLH1 promoter hypermethylation, induced deficient mismatch repair, successfully treated with an immune checkpoint inhibitorKoushiro Ohtsubo, Shigeki Sato, Hiroyuki Sakaguchi, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 24, 2020
Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung CancerSachiko Arai, Shinji Takeuchi, Koji Fukuda, et al.Nature Communications|December 5, 2015
Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumabAtsushi Mitsuhashi, Hisatsugu Goto, Atsuro Saijo, et al.Cancer Research|February 10, 2019
Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation StatusKoji Fukuda, Shinji Takeuchi, Sachiko Arai, et al.Pageof 29